[Form 4] Cytokinetics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cytokinetics Inc. (CYTK) reports a non-derivative equity award to director James M. Daly. On 08/19/2025 Mr. Daly received a non-qualified stock option to purchase 27,450 shares of common stock with an exercise price of $37.84 per share. The option becomes exercisable on 09/19/2025 and expires on 08/19/2035. Following the reported transaction, Mr. Daly beneficially owns 27,450 shares underlying the option as a direct position. The filing states this was an initial grant to a new director.

Positive

• Initial grant to a new director: a non-qualified option for 27,450 underlying shares is documented

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director equity grant aligns new director with shareholder interests; not materially dilutive on its face.

The Form 4 documents an initial non-qualified stock option grant of 27,450 shares to James M. Daly as a new director. The option has a $37.84 exercise price, a 09/19/2025 vesting/exercisable date and a 08/19/2035 expiration. As presented, this is a standard component of director compensation intended to provide equity alignment. The grant size and terms are explicitly stated; the filing does not include additional context such as vesting schedule beyond the exercisable date or whether the award was approved under a specific plan, so implications for share count dilution are not quantifiable from this document alone.

Compensation Analyst

TL;DR: Compensation move is routine; details are specific but lack broader plan context to assess cost.

The disclosure records a non-qualified option for 27,450 underlying shares at $37.84, exercisable beginning 09/19/2025 and expiring 08/19/2035. The form explicitly notes it is an initial grant to a new director. Without the company’s director compensation policy or total share reserve information in this filing, the grant appears as a customary equity award but its relative size versus peer directors or plan limits cannot be determined here.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly James M

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$37.84	08/19/2025		A(1)		27,450		09/19/2025	08/19/2035	Common Stock	27,450	$0	27,450	D

Explanation of Responses:

1. Initial Grant to New Director.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Daly	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did James M. Daly report on CYTK Form 4?

The Form 4 reports a non-qualified stock option granted to James M. Daly to purchase 27,450 shares of Cytokinetics common stock.

What is the exercise price and exercisable date for the option reported by James M. Daly?

The option has an exercise price of $37.84 and becomes exercisable on 09/19/2025.

When does the option expire for the grant to James M. Daly?

The reported option expiration date is 08/19/2035.

How many shares does James M. Daly beneficially own following the reported transaction?

Following the reported transaction, Mr. Daly beneficially owns 27,450 shares underlying the option as a direct holding.

Was this grant described as part of a director appointment or other action?

Yes, the filing includes the explanation: Initial Grant to New Director.